ARTICLE | Company News
Amgen, Epix autoimmune news
October 17, 2011 7:00 AM UTC
Amgen will sell the assets of the partners' sphingosine 1-phosphate receptor 1 ( S1PR1; S1P1; EDG1) agonists program in a sealed bid sale on Dec. 8. Amgen said the decision was based on its portfolio prioritization in 2009. The program includes two S1P1 agonists in preclinical testing for multiple sclerosis (MS): AMG 277 and AMG 369, which also has selectivity over sphingosine 1-phosphate receptor 3 ( S1PR3; S1P3; EDG3). ...